Yes, @jamie.
The Lyme studies are relevant. They are possibly suggestive of how the NIH has acted, and continues to act.
Incidentally, the four RCTs could be interpreted as just three, and at least two of those three did show improvement.
Still, there were inescapable flaws, and an apparent willingness to ignore the outcries of patient advocacies. The arguable result may be upwards of 60,000 Lyme patients each year who remain ill after conventional therapy fails them, many of whom are shunned by insurance carriers and medical establishments.
The ME/CFS community would be unwise to imagine that it is insulated from the same sort of shenanigans.
The Lyme studies are relevant. They are possibly suggestive of how the NIH has acted, and continues to act.
Incidentally, the four RCTs could be interpreted as just three, and at least two of those three did show improvement.
Still, there were inescapable flaws, and an apparent willingness to ignore the outcries of patient advocacies. The arguable result may be upwards of 60,000 Lyme patients each year who remain ill after conventional therapy fails them, many of whom are shunned by insurance carriers and medical establishments.
The ME/CFS community would be unwise to imagine that it is insulated from the same sort of shenanigans.